BSEParmax Pharma LtdHighNeutral
Announced Sat, 2 May · 17:59 IST

Re-appointment of Mr. Umang Gosalia as a Managing Director of the Company

Management Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.7%1-day move
₹30.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+6.7+8.3+6.0+10.0+9.1+6.7+23.3+69.3+181.8
Up moveDown movePending
AI summary

Parmax Pharma Ltd has announced the re-appointment of Dr. Umang Gosalia as Managing Director for another 5-year term starting June 28, 2026 till June 27, 2031. The appointment is subject to shareholder approval at the upcoming AGM/EGM. Dr. Gosalia holds a Ph.D. in Organic Chemistry and has over 1.5 decades of experience in chemistry and production activities. He has been associated with the company since 2016 and is currently responsible for all production activities. The board's Nomination and Remuneration Committee recommended this re-appointment, which was approved at the board meeting held on May 02, 2026.

Likely market impact

This is a routine corporate governance update ensuring leadership continuity at Parmax Pharma. The re-appointment of an experienced Managing Director with a long tenure is generally positive for operational stability. No immediate impact on stock price expected as this is a continuation of existing leadership subject to standard shareholder approval.